139 related articles for article (PubMed ID: 28437610)
1. Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy.
Chen W; Wang G; Yung BC; Liu G; Qian Z; Chen X
ACS Nano; 2017 May; 11(5):5062-5069. PubMed ID: 28437610
[TBL] [Abstract][Full Text] [Related]
2. Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes.
He Z; Hu Y; Gui Z; Zhou Y; Nie T; Zhu J; Liu Z; Chen K; Liu L; Leong KW; Cao P; Chen Y; Mao HQ
J Control Release; 2019 May; 301():119-128. PubMed ID: 30894322
[TBL] [Abstract][Full Text] [Related]
3. C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice.
Tang D; Tian H; Wu J; Cheng J; Luo C; Sai W; Song X; Gao X; Yao W
J Pharmacol Sci; 2018 Sep; 138(1):23-30. PubMed ID: 30309736
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z
Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908
[TBL] [Abstract][Full Text] [Related]
5. Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy.
Chen W; Tian R; Xu C; Yung BC; Wang G; Liu Y; Ni Q; Zhang F; Zhou Z; Wang J; Niu G; Ma Y; Fu L; Chen X
Nat Commun; 2017 Nov; 8(1):1777. PubMed ID: 29176623
[TBL] [Abstract][Full Text] [Related]
6. Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.
Xu S; Wang F; Li H; Wang Y; Fang D
Bioengineered; 2022 Mar; 13(3):4621-4633. PubMed ID: 34696658
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
Lee J; Lee C; Kim I; Moon HR; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Int J Pharm; 2012 Mar; 424(1-2):50-7. PubMed ID: 22226877
[TBL] [Abstract][Full Text] [Related]
8. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
9. Sustained Release of Exendin 4 Using Injectable and Ionic-Nano-Complex Forming Polymer Hydrogel System for Long-Term Treatment of Type 2 Diabetes Mellitus.
Seo BB; Park MR; Song SC
ACS Appl Mater Interfaces; 2019 May; 11(17):15201-15211. PubMed ID: 30945843
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
Ahn S; Lee IH; Lee E; Kim H; Kim YC; Jon S
J Control Release; 2013 Sep; 170(2):226-32. PubMed ID: 23747732
[TBL] [Abstract][Full Text] [Related]
11. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
Lee J; Lee C; Kim TH; Chi SC; Moon HR; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2012 Aug; 177(1-3):68-72. PubMed ID: 22561689
[TBL] [Abstract][Full Text] [Related]
13. Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).
Park EJ; Lim SM; Lee KC; Na DH
Expert Opin Ther Pat; 2016 Jul; 26(7):833-42. PubMed ID: 27196800
[TBL] [Abstract][Full Text] [Related]
14. Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568.
Drugs R D; 2004; 5(1):35-40. PubMed ID: 14725490
[TBL] [Abstract][Full Text] [Related]
15. Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin.
Bae HD; Kim M; Lee J; Lee K
Drug Deliv; 2018 Nov; 25(1):1579-1584. PubMed ID: 30044154
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
18. Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.
Tully M; Wedepohl S; Kutifa D; Weise C; Licha K; Schirner M; Haag R
Eur J Pharm Biopharm; 2021 Jul; 164():105-113. PubMed ID: 33957224
[TBL] [Abstract][Full Text] [Related]
19. Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.
Oh KS; Kim JY; Yoon BD; Lee M; Kim H; Kim M; Seo JH; Yuk SH
Eur J Pharm Biopharm; 2014 Nov; 88(3):664-9. PubMed ID: 25152212
[TBL] [Abstract][Full Text] [Related]
20. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
Chae SY; Jin CH; Shin JH; Son S; Kim TH; Lee S; Youn YS; Byun Y; Lee MS; Lee KC
J Control Release; 2010 Mar; 142(2):206-13. PubMed ID: 19900495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
